Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy

Abstract

Immune checkpoint inhibitors (ICIs) achieve a milestone in cancer treatment. Despite the great success of ICI, ICI therapy still faces a big challenge due to heterogeneity of tumor, and therapeutic response is complicated by possible immune-related adverse events (irAEs). Therefore, it is critical to assess the systemic immune response elicited by ICI therapy to guide subsequent treatment regimens. Positron emission tomography (PET) molecular imaging is an optimal approach in cancer diagnosis, treatment effect evaluation, follow-up, and prognosis prediction. PET imaging can monitor metabolic changes of immunocytes and specifically identify immuno-biomarkers to reflect systemic immune responses. Here, we briefly review the application of PET molecular imaging to date of systemic immune responses following ICI therapy and the associated rationale.

Light on Alzheimer’s disease: from basic insights to preclinical studies

“…PET imaging serves as a vital tool for tumor imaging ( Subramaniam et al, 2009 ; Davison et al, 2011 ; Dibble et al, 2012 ; Romesser et al, 2012 ; Agarwal et al, 2013 ; Davison et al, 2013 ; Heydarheydari et al, 2023 ; Lei et al, 2023 ; Xing et al, 2023 ) and is also an advanced diagnostic technique for brain imaging. It has the capability to offer details about the cerebral glucose metabolism rate during periods of rest, serving as an indicator of neural activity.…”